Hacene K - Search Results

1

Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma.

Bougnoux P, Chajes V, Lanson M, Hacene K, Body G, Couet C, Le Floch O. Bougnoux P, et al. Among authors: hacene k. Breast Cancer Res Treat. 1992 Mar;20(3):185-94. doi: 10.1007/BF01834624. Breast Cancer Res Treat. 1992. PMID: 1571571

2

Epidermal growth factor receptors and prognosis in primary breast cancer.

Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champème MH, Hacène K, Brunet M. Spyratos F, et al. Among authors: hacene k. Breast Cancer Res Treat. 1990 Dec;17(2):83-9. doi: 10.1007/BF01806288. Breast Cancer Res Treat. 1990. PMID: 2096996

3

Survival effect of systemic therapy on patients developing metastatic breast carcinoma.

Rouesse J, Friedman S, Guash-Jordan I, Hacene K, Brunet M. Rouesse J, et al. Among authors: hacene k. Breast Cancer Res Treat. 1990 Jan;15(1):13-20. doi: 10.1007/BF01811885. Breast Cancer Res Treat. 1990. PMID: 2328326

4

Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer.

Pichon MF, Pallud C, Hacene K, Milgrom E. Pichon MF, et al. Among authors: hacene k. Eur J Cancer. 1992;28A(10):1676-80. doi: 10.1016/0959-8049(92)90067-c. Eur J Cancer. 1992. PMID: 1389484

5

Nuclear characteristics as indicators of prognosis in node negative breast cancer patients.

le Doussal V, Tubiana-Hulin M, Hacene K, Friedman S, Brunet M. le Doussal V, et al. Among authors: hacene k. Breast Cancer Res Treat. 1989 Nov;14(2):207-16. doi: 10.1007/BF01810737. Breast Cancer Res Treat. 1989. PMID: 2605347

6

Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Correlation with prognosis and adjuvant hormone therapy.

Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E. Predine J, et al. Among authors: hacene k. Cancer. 1992 Apr 15;69(8):2116-23. doi: 10.1002/1097-0142(19920415)69:8<2116::aid-cncr2820690818>3.0.co;2-b. Cancer. 1992. PMID: 1544118

7

Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay--a retrospective study.

Spyratos F, Martin PM, Hacène K, Andrieu C, Romain S, Floiras JL, Magdelénat H. Spyratos F, et al. Among authors: hacene k. Breast Cancer Res Treat. 1994 Jan;29(1):85-95. doi: 10.1007/BF00666184. Breast Cancer Res Treat. 1994. PMID: 8018965 Clinical Trial.

8

Multiparametric prognostic evaluation of biological factors in primary breast cancer.

Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, Le Doussal V, Tubiana-Hulin M, Brunet M. Spyratos F, et al. Among authors: hacene k. J Natl Cancer Inst. 1992 Aug 19;84(16):1266-72. doi: 10.1093/jnci/84.16.1266. J Natl Cancer Inst. 1992. PMID: 1640487

9

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Bouchet C, et al. Among authors: hacene k. Br J Cancer. 1994 Feb;69(2):398-405. doi: 10.1038/bjc.1994.74. Br J Cancer. 1994. PMID: 8297742 Free PMC article.

10

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

Bouchet C, Spyratos F, Hacène K, Durcos L, Bécette V, Oglobine J. Bouchet C, et al. Among authors: hacene k. Br J Cancer. 1998 May;77(9):1495-501. doi: 10.1038/bjc.1998.246. Br J Cancer. 1998. PMID: 9652768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters